Floatz logo

Ulixertinib

MAP2K1 Gene Mutation

BioMed Valley Discoveries, IncSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the MAP2K1 Gene Mutation cohort.

Asset / SponsorPhaseRating
gsk1120212
M.D. Anderson Cancer Center
Phase 2CCC
PANITUMUMAB
M.D. Anderson Cancer Center
Phase 2CCC

Same molecule, other indications

Ulixertinib is also rated in:

neoplasmDormant
B
Indicative ·
57 / 100
View asset →
lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
rectal carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →